
    
      A multi-centre, multi-national, open label trial of Forodesine in children with relapsed or
      refractory T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's
      Lymphoma. The primary objective of the study is to evaluate the pharmacokinetics and
      pharmacodynamics of six different dose schedules of Forodesine. Secondary objectives are to
      evaluate safety and to collect preliminary efficacy data. All patients will receive active
      drug. The Initial Treatment Phase will last 37 days with a final response assessment on Day
      37. Patients who achieve a response may be eligible to receive extended treatment with
      Forodesine for up to 6 months.
    
  